192 related articles for article (PubMed ID: 35648811)
1. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy.
Yang S; Li T; Jia H; Gao M; Li Y; Wan X; Huang Z; Li M; Zhai Y; Li X; Yang X; Wang T; Liang J; Gu Q; Luo X; Qian L; Lu S; Liu J; Song Y; Wang F; Sun X; Yu D
Sci Transl Med; 2022 Jun; 14(647):eabj2177. PubMed ID: 35648811
[TBL] [Abstract][Full Text] [Related]
2. A Novel Bispecific Fusion Protein Targeting C3b/C4b and VEGF in Patients With nAMD: A Randomized, Open-Label, Phase 1b Study.
Jia H; Li T; Sun J; Gong Y; Liu H; Wang H; Chen J; Liu W; Lu S; Feng L; Wan Q; Qian L; Wang F; Liu X; Sun X
Am J Ophthalmol; 2023 Apr; 248():8-15. PubMed ID: 36410472
[TBL] [Abstract][Full Text] [Related]
3. Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization.
Fu Y; Zhang Z; Webster KA; Paulus YM
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540673
[TBL] [Abstract][Full Text] [Related]
4. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
Lu X; Sun X
Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
6. IBI302, a promising candidate for AMD treatment, targeting both the VEGF and complement system with high binding affinity in vitro and effective targeting of the ocular tissue in healthy rhesus monkeys.
Ren X; Li J; Xu X; Wang C; Cheng Y
Exp Eye Res; 2016 Apr; 145():352-358. PubMed ID: 26919788
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
8. The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.
Teo KYC; Gillies M; Fraser-Bell S
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30177632
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
10. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM; Noureddine BN; Bashshur ZF
Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
[TBL] [Abstract][Full Text] [Related]
12. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
13. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
[TBL] [Abstract][Full Text] [Related]
14. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review.
Yang S; Zhao J; Sun X
Drug Des Devel Ther; 2016; 10():1857-67. PubMed ID: 27330279
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood mononuclear cells from neovascular age-related macular degeneration patients produce higher levels of chemokines CCL2 (MCP-1) and CXCL8 (IL-8).
Lechner J; Chen M; Hogg RE; Toth L; Silvestri G; Chakravarthy U; Xu H
J Neuroinflammation; 2017 Feb; 14(1):42. PubMed ID: 28231837
[TBL] [Abstract][Full Text] [Related]
16. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
17. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.
Hashemi S; Faramarzi MA; Ghasemi Falavarjani K; Abdollahi M
Expert Opin Biol Ther; 2014 Dec; 14(12):1837-48. PubMed ID: 25283631
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration.
Nguyen QD; Shah SM; Browning DJ; Hudson H; Sonkin P; Hariprasad SM; Kaiser P; Slakter JS; Haller J; Do DV; Mieler WF; Chu K; Yang K; Ingerman A; Vitti RL; Berliner AJ; Cedarbaum JM; Campochiaro PA
Ophthalmology; 2009 Nov; 116(11):2141-8.e1. PubMed ID: 19700196
[TBL] [Abstract][Full Text] [Related]
20. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
